Trial Number

681-26

Condition

Lung Cancer

Participant Age Range

18 years and older

Participant Gender

Any

Enrolling Participants

Yes

Overview

“ROSETTA Lung-220: A Phase 2, Open-Label, Multicenter, Multi-Arm Platform Study Evaluating Pumitamig and Other Novel Neoadjuvant Regimens in Participants With Resectable, Early-Stage (IIA to IIIB) Non-Small Cell Lung Cancer”

Researchers are studying an investigational medication called pumitamig, given with chemotherapy before surgery, for adults with newly diagnosed, early-stage non-small cell lung cancer (NSCLC) that can be surgically removed. Participants will receive one of two doses of pumitamig with platinum-based chemotherapy for up to four treatment cycles, followed by surgery. Researchers will evaluate how well the treatment eliminates cancer cells from the tumor and lymph nodes, as well as its safety, effects on surgery, and whether the cancer returns. Participants may be followed for up to approximately five years.

Locations

Name
Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
This registration is for:
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.